Profile data is unavailable for this security.
About the company
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
- Revenue in INR (TTM)16.31bn
- Net income in INR761.19m
- Incorporated1984
- Employees1.65k
- LocationMorepen Laboratories LtdVillage Malkumajra, Nalagarh Road,BaddiGURGAON 122016IndiaIND
- Phone+91 1 244892000
- Fax+91 1 123722422
- Websitehttp://www.morepen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 15.81bn | 343.00 | 41.60 | -- | 31.80 | 4.99 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| Solara Active Pharma Sciences Ltd | 14.07bn | -3.08bn | 17.06bn | 2.36k | -- | -- | -- | 1.21 | -85.65 | -85.65 | 390.73 | -- | -- | -- | -- | 5,958,916.00 | -- | 2.68 | -- | 4.10 | 40.47 | 44.49 | -21.88 | 4.58 | -- | -1.67 | -- | 10.10 | 13.83 | 22.61 | 61.86 | -- | 26.23 | -- |
| SMS Pharmaceuticals Ltd | 6.13bn | 360.58m | 17.48bn | 1.10k | 48.44 | -- | 24.16 | 2.85 | 4.26 | 4.26 | 72.40 | -- | -- | -- | -- | 5,597,176.00 | -- | 5.86 | -- | 7.77 | 31.67 | 33.18 | 6.65 | 8.34 | -- | 3.13 | -- | 6.26 | 0.4188 | 2.35 | -111.35 | -- | 28.46 | 3.71 |
| Amrutanjan Health Care Ltd | 3.94bn | 440.09m | 18.57bn | 575.00 | 42.53 | -- | 37.25 | 4.71 | 15.13 | 15.13 | 135.41 | -- | -- | -- | -- | 6,860,612.00 | -- | 17.04 | -- | 21.22 | 49.51 | 54.08 | 11.16 | 13.37 | -- | 341.76 | -- | 17.21 | -6.46 | 11.37 | -40.71 | 14.72 | 23.87 | 10.64 |
| Themis Medicare Ltd | 3.64bn | 452.86m | 19.36bn | 996.00 | 42.82 | -- | 33.80 | 5.32 | 4.91 | 4.91 | 39.49 | -- | -- | -- | -- | 3,655,101.00 | -- | 9.59 | -- | 14.94 | 65.58 | 60.13 | 12.44 | 13.15 | -- | -- | -- | 7.33 | -10.21 | 10.85 | -21.93 | 38.18 | 24.51 | -- |
| Morepen Laboratories Ltd | 16.31bn | 761.19m | 23.82bn | 1.65k | 30.88 | -- | 22.27 | 1.46 | 1.51 | 1.51 | 32.53 | -- | -- | -- | -- | 9,891,111.00 | -- | 7.39 | -- | 13.78 | 35.85 | 32.82 | 4.67 | 5.19 | -- | 27.34 | -- | 0.00 | -8.36 | 18.51 | -61.96 | 5.50 | 11.33 | -- |
| Suven Life Sciences Ltd | 119.19m | -1.06bn | 23.99bn | 132.00 | -- | -- | -- | 201.26 | -5.20 | -5.20 | 0.5759 | -- | -- | -- | -- | 902,939.40 | -- | -31.29 | -- | -35.32 | -- | 66.93 | -890.87 | -127.02 | -- | -744.27 | -- | -- | 14.31 | -53.54 | 3.06 | -- | -41.37 | -- |
| RPG Life Sciences Limited | 5.74bn | 847.70m | 25.00bn | 1.17k | 29.49 | -- | 24.69 | 4.36 | 51.26 | 51.26 | 346.80 | -- | -- | -- | -- | -- | -- | 13.08 | -- | 18.26 | 68.17 | 62.42 | 14.78 | 9.71 | -- | 296.86 | -- | 29.26 | 16.51 | 8.12 | 31.39 | 38.13 | 16.15 | 37.97 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 26.31bn | 1.23k | -- | 83.22 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Innova Captab Ltd | -100.00bn | -100.00bn | 27.37bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.72 | -- | 6.26 | -- | -- | -- |
| Supriya Lifescience Ltd | 5.54bn | 1.20bn | 29.51bn | 392.00 | 24.49 | -- | 21.81 | 5.32 | 14.97 | 14.97 | 68.93 | -- | -- | -- | -- | 14,144,410.00 | -- | 20.77 | -- | 29.06 | 61.94 | 55.83 | 21.72 | 24.33 | -- | 63.63 | -- | 2.02 | -13.04 | 16.70 | -40.81 | 59.41 | 85.55 | -- |
| SeQuent Scientific Ltd | 13.75bn | -1.29bn | 29.71bn | 478.00 | -- | -- | -- | 2.16 | -5.18 | -5.18 | 55.33 | -- | -- | -- | -- | 28,769,920.00 | -- | 2.33 | -- | 3.67 | 42.78 | 42.47 | -8.97 | 2.59 | -- | -0.3894 | -- | 17.27 | 0.5728 | 10.84 | -395.83 | -- | 12.88 | -- |
| Indoco Remedies Ltd | 17.96bn | 1.02bn | 30.59bn | 6.10k | 30.37 | -- | 16.62 | 1.70 | 10.93 | 10.93 | 192.26 | -- | -- | -- | -- | 2,943,454.00 | -- | 6.07 | -- | 8.90 | 69.39 | 65.35 | 5.61 | 6.30 | -- | 5.11 | -- | 14.79 | 8.30 | 9.81 | -8.11 | 28.15 | 8.25 | 17.61 |
| Gufic BioSciences Ltd | 7.85bn | 841.95m | 30.64bn | 1.63k | 35.44 | -- | 29.05 | 3.90 | 8.62 | 8.62 | 80.38 | -- | -- | -- | -- | 4,820,074.00 | -- | 12.30 | -- | 23.08 | 51.08 | 44.91 | 10.73 | 9.84 | -- | 8.22 | -- | 1.39 | -11.36 | 17.47 | -16.84 | 37.06 | 86.82 | 14.87 |
Data as of Apr 19 2024. Currency figures normalised to Morepen Laboratories Ltd's reporting currency: Indian Rupee INR
1.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 4.94m | 0.97% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 477.64k | 0.09% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 470.99k | 0.09% |
| DFA Australia Ltd.as of 31 Dec 2023 | 18.37k | 0.00% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 5.63k | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 3.52k | 0.00% |
More ▼
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
